← Leaderboards
Stephen David Nimer
Sloan-Kettering Institute For Cancer Res
$17,329,022
Attributed
$17,329,022
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,783,707 · 14
By mechanism
P30$22,967,580 · 7
R01$11,938,857 · 5
R56$500,000 · 1
P01$377,270 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsInsightFundingGrowthTranscription FactorTranslational ResearchProgramsEpigenetic ProcessClinical ResearchStrategic PlanningCatchment AreaResource SharingCancer Center Support GrantComprehensive Cancer CenterAffectBaseLeadershipCommunity OutreachGrantInvestmentsMissionRecruitPopulation SciencesMember
Grant awards (67)
The Sylvester Cancer Center Support Grant$3,019,497
P30 · FY2025 · CA · contact PI
Developmental Funds$488,210
P30 · FY2025 · CA · contact PI
Targeted therapy for t(8;21)+ AML$448,823
R01 · FY2025 · CA · contact PI
Leadership, Planning and Evaluation$273,812
P30 · FY2025 · CA · contact PI
The Sylvester Cancer Center Support Grant$2,827,616
P30 · FY2024 · CA · contact PI
Targeted therapy for t(8;21)+ AML$457,843
R01 · FY2024 · CA · contact PI
Developmental Funds$415,402
P30 · FY2024 · CA · contact PI
Dependency of AML on CARM1 activity$370,596
R01 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$232,979
P30 · FY2024 · CA · contact PI
The Sylvester Cancer Center Support Grant$191,875
P30 · FY2024 · CA · contact PI
The Sylvester Cancer Center Support Grant$2,149,002
P30 · FY2023 · CA · contact PI
Developmental Funds$415,991
P30 · FY2023 · CA · contact PI
Dependency of AML on CARM1 activity$382,298
R01 · FY2023 · CA · contact PI
The Sylvester Cancer Center Support Grant$214,900
P30 · FY2023 · CA · contact PI
The Impact of Perioperative Opioids on the Gut Estrobolome in Breast Cancer Patientsâ¯$191,875
P30 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$167,470
P30 · FY2023 · CA · contact PI
The Sylvester Cancer Center Support Grant$2,149,003
P30 · FY2022 · CA · contact PI
Developmental Funds$465,539
P30 · FY2022 · CA · contact PI
Dependency of AML on CARM1 activity$382,296
R01 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$163,526
P30 · FY2022 · CA · contact PI
The Sylvester Cancer Center Support Grant$2,147,554
P30 · FY2021 · CA · contact PI
Developmental Funds$466,597
P30 · FY2021 · CA · contact PI
Dependency of AML on CARM1 activity$390,100
R01 · FY2021 · CA · contact PI
Targeted Therapy for t(8;21)+ AML$345,375
R01 · FY2021 · CA · contact PI
Leadership, Planning and Evaluation$159,700
P30 · FY2021 · CA · contact PI
The Sylvester Cancer Center Support Grant$124,829
P30 · FY2021 · CA · contact PI
The Sylvester Cancer Center Support Grant$2,149,002
P30 · FY2020 · CA · contact PI
The Sylvester Cancer Center Support Grant$767,500
P30 · FY2020 · CA · contact PI
Developmental Funds$471,073
P30 · FY2020 · CA · contact PI
Dependency of AML on CARM1 activity$390,100
R01 · FY2020 · CA · contact PI
Targeted Therapy for t(8;21)+ AML$345,375
R01 · FY2020 · CA · contact PI
Leadership, Planning and Evaluation$155,987
P30 · FY2020 · CA · contact PI
The Sylvester Cancer Center Support Grant$150,000
P30 · FY2020 · CA · contact PI
The Sylvester Cancer Center Support Grant$123,033
P30 · FY2020 · CA · contact PI
The Sylvester Cancer Center Support Grant$100,001
P30 · FY2020 · CA · contact PI
The Sylvester Cancer Center Support Grant$2,148,998
P30 · FY2019 · CA · contact PI
Developmental Funds$484,223
P30 · FY2019 · CA · contact PI
Targeted Therapy for t(8;21)+ AML$335,013
R01 · FY2019 · CA · contact PI
Leadership, Planning and Evaluation$152,386
P30 · FY2019 · CA · contact PI
Targeted Therapy for t(8;21)+ AML$345,375
R01 · FY2018 · CA · contact PI
Targeted Therapy for t(8;21)+ AML$345,375
R01 · FY2017 · CA · contact PI
Targeting p300 and lysine acetylation in AML$317,475
R01 · FY2016 · CA · contact PI
Targeting p300 and lysine acetylation in AML$317,475
R01 · FY2015 · CA · contact PI
Targeting p300 and lysine acetylation in AML$307,951
R01 · FY2014 · CA · contact PI
Targeting p300 and lysine acetylation in AML$298,427
R01 · FY2013 · CA · contact PI
Targeting p300 and lysine acetylation in AML$317,475
R01 · FY2012 · CA · contact PI
Function of MEF in Hematopoietic Cells$286,363
R01 · FY2011 · DK · contact PI
Function of MEF in Hematopoietic Cells$96,926
R01 · FY2011 · DK · contact PI
Function of MEF in Hematopoietic Cells$398,871
R01 · FY2010 · DK · contact PI
Function of MEF in Hematopoietic Cells$402,900
R01 · FY2009 · DK · contact PI
Function of MEF in Hematopoietic Cells$403,219
R01 · FY2008 · DK · contact PI
Function of MEF in Hematopoietic Cells$500,000
R56 · FY2007 · DK · contact PI
The function of I(3)mbt in hematopoietic cancers$385,231
R01 · FY2007 · CA · contact PI
The function of I(3)mbt in hematopoietic cancers$366,102
R01 · FY2006 · CA · contact PI
The function of I(3)mbt in hematopoietic cancers$374,913
R01 · FY2005 · CA
Function of MEF in Hematopoietic Cells$331,216
R01 · FY2005 · DK
The function of I(3)mbt in hematopoietic cancers$374,913
R01 · FY2004 · CA
Function of MEF in Hematopoietic Cells$331,216
R01 · FY2004 · DK
Vitamin D3 inducible Genes Mediating Differentiation$285,250
R01 · FY2004 · DK
The function of I(3)mbt in hematopoietic cancers$373,800
R01 · FY2003 · CA
Function of MEF in Hematopoietic Cells$331,216
R01 · FY2003 · DK
Vitamin D3 inducible Genes Mediating Differentiation$285,250
R01 · FY2003 · DK
Function of MEF in Hematopoietic Cells$348,728
R01 · FY2002 · DK
Vitamin D3 inducible Genes Mediating Differentiation$285,250
R01 · FY2002 · DK
HEMATOLOGIC ONCOLOGY$188,635
P01 · FY2002 · CA
HEMATOLOGIC ONCOLOGY$188,635
P01 · FY2001 · CA
FUNCTION OF MEF IN HEMATOPOIETIC CELLS$180,121
R01 · FY2000 · DK